ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 313,56
-0,57%
Dow Jones
42 672,78
-0,74%
DAX
19 909,14
-0,25%
Brent Oil
74,46
1,13%
Bitcoin
92 039,03
-1,58%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Aclaris Therapeutics Inc (ACRS) Cours

Aclaris Therapeutics Inc

Aclaris Therapeutics Inc (ACRS)

NASDAQ
2,5805
-0,1495
( -5,48% )
Mis à jour : 17:58:01
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
2,5805
Prix Achat
2,58
Prix Vente
2,59
Volume échangé
282 301
2,535 Fourchette du Jour 2,74
0,8555 Plage de 52 semaines 5,17
Cap du marché
184,328M
Clôture Veille
2,73
Ouverture
2,68
Dernière Transaction
3
@
2.5827
Dernière heure de transaction
17:58:10
Volume financier
US$ 729 241
VWAP
2,5832
Volume moyen (3 m)
2 590 960
Actions en circulation
71 430 942
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,09
Bénéfice par action (BPA)
-1,24
Chiffre d'affairess
31,25M
Bénéfice net
-88,48M

À propos de Aclaris Therapeutics Inc

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from... Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.aclaristx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Aclaris Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ACRS. Le dernier cours de clôture d'Aclaris Therapeutics était de US$2,73. Au cours de la dernière année, les actions de Aclaris Therapeutics ont été négociées dans une fourchette de prix de US$ 0,8555 à US$ 5,17.

Aclaris Therapeutics compte actuellement 71 430 942 actions en circulation. La capitalisation boursière d'Aclaris Therapeutics est de US$195,01 million. Aclaris Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.09.

ACRS Dernières nouvelles

Plus de nouvelles

Form S-3 - Registration statement under Securities Act of 1933

19 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

06 Décembre 2024
Edgar (US Regulatory)

Form D - Notice of Exempt Offering of Securities

04 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Décembre 2024
Edgar (US Regulatory)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug...

03 Décembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

03 Décembre 2024
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

27 Novembre 2024
Edgar (US Regulatory)

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...

26 Novembre 2024
GlobeNewswire Inc.

Form 3 - Initial statement of beneficial ownership of securities

25 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.4095-13.69565217392.993.122.5359023082.87216033CS
4-1.4695-36.28395061734.054.1652.5359506063.32070935CS
121.4005118.6864406781.185.171.1225909603.58061283CS
261.4805134.5909090911.15.171.114879733.13507175CS
521.4805134.5909090911.15.170.855513504042.26707727CS
156-11.9295-82.215713301214.5118.95830.590211878584.73259104CS
2600.650533.70466321241.9330.3750.590210565737.58354874CS

ACRS - Frequently Asked Questions (FAQ)

What is the current Aclaris Therapeutics share price?
The current share price of Aclaris Therapeutics is US$ 2,5805
How many Aclaris Therapeutics shares are in issue?
Aclaris Therapeutics has 71 430 942 shares in issue
What is the market cap of Aclaris Therapeutics?
The market capitalisation of Aclaris Therapeutics is USD 195,01M
What is the 1 year trading range for Aclaris Therapeutics share price?
Aclaris Therapeutics has traded in the range of US$ 0,8555 to US$ 5,17 during the past year
What is the PE ratio of Aclaris Therapeutics?
The price to earnings ratio of Aclaris Therapeutics is -2,09
What is the cash to sales ratio of Aclaris Therapeutics?
The cash to sales ratio of Aclaris Therapeutics is 5,92
What is the reporting currency for Aclaris Therapeutics?
Aclaris Therapeutics reports financial results in USD
What is the latest annual turnover for Aclaris Therapeutics?
The latest annual turnover of Aclaris Therapeutics is USD 31,25M
What is the latest annual profit for Aclaris Therapeutics?
The latest annual profit of Aclaris Therapeutics is USD -88,48M
What is the registered address of Aclaris Therapeutics?
The registered address for Aclaris Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Aclaris Therapeutics website address?
The website address for Aclaris Therapeutics is www.aclaristx.com
Which industry sector does Aclaris Therapeutics operate in?
Aclaris Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NXUNXU Inc
US$ 1,4301
(487,55%)
385,81M
WATTEnergous Corporation
US$ 1,605
(290,32%)
159,58M
INTZIntrusion Inc
US$ 5,78
(167,59%)
109,65M
CYNCYNGN Inc
US$ 1,2697
(102,21%)
57,71M
HOLOMicroCloud Hologram Inc
US$ 4,47
(86,25%)
87,54M
ABPAbpro Holdings Inc
US$ 2,1699
(-51,67%)
1,32M
TRAWTraws Pharma Inc
US$ 7,595
(-43,41%)
879,38k
LITMSnow Lake Resources Ltd
US$ 1,0894
(-31,91%)
43,49M
LGHLWLion Group Holding Ltd
US$ 0,0052
(-25,71%)
54,74k
BITSGlobal X Blockchain and Bitcoin Stratagy ETF
US$ 66,81
(-24,48%)
8,74k
NXUNXU Inc
US$ 1,4494
(495,48%)
382,52M
VINCVincerx Inc
US$ 0,35
(80,41%)
290,62M
XTIAXTI Aerospace Inc
US$ 0,03995
(1,14%)
164,99M
WATTEnergous Corporation
US$ 1,61
(291,54%)
158,84M
SMXSMX Security Matters Public Company
US$ 0,6311
(78,48%)
111,03M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
ACRS
Aclaris Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés